NASDAQ:HOTHHoth Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hoth Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.84 -0.10 (-3.40 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$2.82Now: $2.84▼$2.9450-Day Range$2.80MA: $3.39▼$4.0852-Week Range$2.60Now: $2.84▼$9.07Volume554,400 shsAverage Volume319,640 shsMarket Capitalization$32.95 millionP/E RatioN/ADividend YieldN/ABeta1.11 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Hoth Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company was incorporated in 2017 and is based in New York.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingHoth Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Hoth Therapeutics has a potential upside of 252.1% from its current price of $2.84.Amount of Analyst CoverageHoth Therapeutics has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesHoth Therapeutics has received 55 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHoth Therapeutics has received 62 “underperform” votes. (Add your “underperform” vote.)Community SentimentHoth Therapeutics has received 52.99% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Hoth Therapeutics and other stocks. Vote “Outperform” if you believe HOTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HOTH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHoth Therapeutics does not currently pay a dividend.Dividend GrowthHoth Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hoth Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $500,000.00 in company stock.Percentage Held by InstitutionsOnly 0.28% of the stock of Hoth Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hoth Therapeutics are expected to grow in the coming year, from ($0.85) to $0.00 per share.Price to Book Value per Share RatioHoth Therapeutics has a P/B Ratio of 6.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOTH Previous Symbol CUSIPN/A CIKN/A Webwww.hoththerapeutics.com Phone646-756-2997Debt Debt-to-Equity RatioN/A Current Ratio9.36 Quick Ratio9.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book6.76Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,700,000.00 Net MarginsN/A Return on Equity-221.49% Return on Assets-205.42%Miscellaneous Employees2 Outstanding Shares11,602,000Market Cap$32.95 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:HOTH Rates by TradingView Receive HOTH News and Ratings via Email Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions How has Hoth Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HOTH shares have decreased by 26.0% and is now trading at $2.84. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Hoth Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hoth Therapeutics. When is Hoth Therapeutics' next earnings date? Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Hoth Therapeutics. How were Hoth Therapeutics' earnings last quarter? Hoth Therapeutics Inc (NASDAQ:HOTH) posted its earnings results on Wednesday, May, 13th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. View Hoth Therapeutics' earnings history. What price target have analysts set for HOTH? 1 equities research analysts have issued twelve-month price objectives for Hoth Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Hoth Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 252.1% from the stock's current price. View analysts' price targets for Hoth Therapeutics. Has Hoth Therapeutics been receiving favorable news coverage? Press coverage about HOTH stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hoth Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutHoth Therapeutics. Are investors shorting Hoth Therapeutics? Hoth Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 13,000 shares, a decrease of 7.8% from the April 30th total of 14,100 shares. Based on an average trading volume of 265,400 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.2% of the shares of the company are sold short. View Hoth Therapeutics' Current Options Chain. Who are some of Hoth Therapeutics' key competitors? Some companies that are related to Hoth Therapeutics include SUMMIT THERAPEU/S (SMMT), Immunic (IMUX), Zynerba Pharmaceuticals (ZYNE), Savara (SVRA), Endonovo Therapeutics (ENDV), GlycoMimetics (GLYC), PhaseBio Pharmaceuticals (PHAS), Checkpoint Therapeutics (CKPT), Axovant Gene Therapies (AXGT), Aldeyra Therapeutics (ALDX), InflaRx (LUMO), AVEO Pharmaceuticals (AVEO), Cyclerion Therapeutics (CYCN), AcelRx Pharmaceuticals (ACRX) and Helix Biopharma (HBPCF). View all competitors. What other stocks do shareholders of Hoth Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Gilead Sciences (GILD), Citius Pharmaceuticals (CTXR), Inovio Pharmaceuticals (INO), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Pfizer (PFE), Novavax (NVAX), Opko Health (OPK), Verizon Communications (VZ) and AbbVie (ABBV). Who are Hoth Therapeutics' key executives? Hoth Therapeutics' management team includes the following people: Mr. Robb Knie, Pres, CEO & Director (Age 50)Mr. David S. Briones, Chief Financial Officer (Age 43)Ms. Jane H. Behrmann, VP of Operations (Age 34) When did Hoth Therapeutics IPO? (HOTH) raised $8 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. What is Hoth Therapeutics' stock symbol? Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH." How do I buy shares of Hoth Therapeutics? Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Hoth Therapeutics' stock price today? One share of HOTH stock can currently be purchased for approximately $2.84. How big of a company is Hoth Therapeutics? Hoth Therapeutics has a market capitalization of $32.95 million. Hoth Therapeutics employs 2 workers across the globe. What is Hoth Therapeutics' official website? The official website for Hoth Therapeutics is www.hoththerapeutics.com. How can I contact Hoth Therapeutics? Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
